Oral TRT Tlando Jatenzo Kyzatrex Efficacy and Blood Pressure

Oral TRT Tlando Jatenzo Kyzatrex Efficacy and Blood Pressure

See how Tlando, Jatenzo, and Kyzatrex stack up on restoring testosterone, dosing, and side effects. Learn why routine blood pressure checks matter with oral TRT.

Estimated reading time: 10 minutes

Key takeaways

• Oral testosterone undecanoate (TU) capsules—Tlando, Jatenzo, Kyzatrex—restored average testosterone to the eugonadal range for most men in Phase 3 trials.
• Small but consistent systolic blood pressure increases (about 1.7–5 mmHg by ABPM) occur across studies; effects may be larger in men on antihypertensives—monitor BP routinely.
• No hepatotoxicity signals with modern oral TU compared with older 17-alpha-alkylated androgens.
• Dosing differs: Kyzatrex and Jatenzo are titrated; Tlando is fixed-dose (225 mg twice daily). Food effects and adherence matter.
• FDA labeling (post-TRAVERSE) removes the prior boxed warning for MACE and emphasizes a class-wide warning about BP increases.

Overview

Men weighing testosterone therapy increasingly ask about oral options that avoid needles yet reliably restore testosterone. Oral testosterone replacement therapy (TRT) with testosterone undecanoate (TU) capsules—Tlando, Jatenzo, and Kyzatrex—now offers a credible alternative to injections for many hypogonadal men. Phase 3 pharmacokinetic (PK) trials show these formulations can achieve eugonadal testosterone levels with structured dosing and titration, without the liver toxicity associated with older oral androgens. The key nuance: small but measurable increases in blood pressure (BP) have been observed and are now emphasized across product labeling, making BP monitoring an essential part of care.

This article compares what the major oral TU options deliver, what their trial data actually show, and what practical monitoring looks like for real patients.

What Is Oral Testosterone Undecanoate and Why It’s Different

Testosterone undecanoate is a long-chain fatty acid ester of testosterone. Oral TU capsules are absorbed via the intestinal lymphatic system, which helps bypass first-pass hepatic metabolism. That pharmacology is essential to two points men frequently ask about:

• Liver safety: Unlike older oral androgens (for example, 17-alpha-alkylated compounds), modern oral TU formulations in Phase 3 programs have not shown liver toxicity signals.
• Food and absorption: Historically, oral TU has required administration with meals—especially dietary fat—to optimize absorption. While labels differ, men should expect clinicians to discuss meal timing and consistency. Some recent data suggest Kyzatrex may be less dependent on meal fat than older formulations, but patients should follow product-specific guidance.

In routine care, the “oral vs injectable” conversation often comes down to preference (needle-averse, travel, convenience), adherence (twice-daily dosing), and physiology (avoiding supraphysiologic peaks and deep troughs more typical of some injectable regimens).

What the Phase 3 Trials Show

Across the three FDA-approved oral TU capsules, pivotal and supportive studies consistently demonstrate restoration of total testosterone (TT) to target ranges for the majority of treated men. Each product follows its own dosing and titration framework.

• Kyzatrex (MRS-TU-2019EXT; FDA 2022)
  • Population: Hypogonadal men; median age around 50; most were overweight or obese—important when thinking about generalizability.
  • Efficacy: Approximately 87.8% (worst-case) to 96.1% (completers) achieved eugonadal average TT by Day 90. Mean Cavg was about 452 ng/dL, and free T approximately doubled from baseline (roughly 7.0 to 14.1 ng/dL).
  • Dosing: Titrated within 100–400 mg twice daily based on on-therapy testosterone levels.
  • Notes: FDA review documents discuss site-specific data integrity concerns that were addressed in the final efficacy analysis; the Phase 3 extension met prespecified endpoints after excluding a problematic site per protocol.
• Jatenzo (CLAR-15102; FDA 2019)
  • Population: Hypogonadal men studied in a PK-driven Phase 3 program.
  • Efficacy: Met FDA PK criteria for achieving average testosterone in the eugonadal range.
  • Dosing: Typically starts at 237 mg twice daily with subsequent titration based on follow-up labs.
• Tlando (Full FDA approval 2023)
  • Population: Hypogonadal men; program focused on fixed-dose feasibility.
  • Efficacy: A fixed 225 mg twice-daily dose restored eugonadal testosterone without titration.
  • Dosing: Not titrated, which can simplify use for men and clinicians who prefer a fixed approach.

Despite differences in titration philosophy, the overarching story is similar: oral TU reliably normalizes average testosterone in most treated men when dosing is selected and adjusted according to product labeling and measured TT. It is common for clinicians to aim for a mid-normal average TT with symptom improvement while minimizing side effects.

Blood Pressure: Small Increases That Matter Clinically

BP effects are the most consistent class signal across oral TU trials and FDA reviews. Measurements by ambulatory blood pressure monitoring (ABPM) avoid clinic “white coat” effects and give a clearer picture of on-therapy changes:

• Kyzatrex: ABPM showed an average systolic increase of about +1.7 mmHg (95% CI 0.3–3.1) and diastolic +0.6 mmHg at steady state, with a plateau over time. In men already on antihypertensives, the systolic increase was larger (about +3.4 mmHg).
• Jatenzo and Tlando: FDA reviewers report average systolic increases roughly in the 3–5 mmHg range on ABPM, depending on the study cohort and time point.

How should patients interpret this? On an individual level, a few mmHg may or may not move a person across a diagnostic threshold—but from a population-health perspective, even small BP rises can matter. Given how common hypertension, diabetes, and obesity are among men seeking TRT, the pragmatic response is not alarm, but routine measurement:

• Establish baseline BP prior to starting oral TRT.
• Check BP periodically on therapy; clinicians increasingly use home BP measurements and ABPM in higher-risk patients.
• Be aware that injectable and transdermal TRT can also affect BP. For context, the weekly subcutaneous testosterone enanthate autoinjector has shown a systolic rise of ~4 mmHg in some studies, so BP considerations are not unique to oral TU.

As of early 2025, FDA labeling reflects outcomes from the large TRAVERSE trial by removing the prior class boxed warning for MACE while adding or highlighting a class-wide warning about BP increases. The net message for patients: TRT does not appear to raise major cardiovascular events overall compared with placebo in appropriately selected men, but modest BP elevations are sufficiently consistent to warrant proactive monitoring.

Titration and Monitoring: What Patients Can Expect

Individualized dosing and regular follow-up are central to safe, effective TRT—oral or otherwise. While exact steps are determined by a prescribing clinician, the Phase 3 programs and FDA labels suggest several practical themes:

• Confirm the diagnosis carefully:
  • Most clinicians confirm low testosterone on two separate morning samples, alongside consistent symptoms, before initiating TRT.
• Choose an oral TU strategy aligned with monitoring preferences:
  • Kyzatrex: Titration within 100–400 mg twice daily, with dose adjustments to keep average TT eugonadal.
  • Jatenzo: Typically starts at 237 mg twice daily, then titrates up or down based on follow-up TT.
  • Tlando: Fixed 225 mg twice daily—no titration—which may simplify follow-up for some men.
• Consider food effects:
  • Many oral TU capsules are taken with food to support absorption. Some data suggest Kyzatrex is less dependent on meal fat than earlier capsules; patients should follow the specific product label and clinician advice.
• Monitor at regular intervals (often every 3–6 months once stable):
  • Testosterone and, when appropriate, free T to verify eugonadal levels.
  • Hematocrit/hemoglobin to watch for erythrocytosis.
  • BP at baseline and on therapy; home BP logs or ABPM can be useful, especially if cardiovascular risk is present.
  • Prostate health monitoring consistent with age and risk (e.g., PSA where indicated).
• Manage comorbidities in parallel:
  • In the oral TU trials, a sizable proportion of men had hypertension, diabetes, or dyslipidemia at baseline; a small fraction started new antihypertensives during the studies. Coordinated primary care and cardiometabolic risk management remain important.

These points are not prescriptive directions; they illustrate the kind of structured, lab-informed care many clinics employ with oral TRT.

Oral TU vs Injectables: Pharmacokinetics and Patient Experience

• Peaks and troughs: Twice-daily oral TU targets steady-state testosterone within the eugonadal window, aiming to minimize the high peaks and low troughs common with some injection schedules. This can matter for symptom stability and side-effect profiles.
• Adherence trade-offs: Oral capsules avoid needles and in-office injections but rely on consistent twice-daily adherence, often with meals, to maintain stable exposure.
• Side effects and risks: Erythrocytosis, acne/oily skin, edema, and reduced fertility potential are class effects to consider, regardless of route. Oral TU has not shown the hepatotoxicity associated with 17-alpha-alkylated androgens.
• Blood pressure: Small BP rises are seen with several TRT modalities. With oral TU, the effect is measurable by ABPM, and labels now call for attention to BP across the class.

For many men who are needle-averse or who prefer a convenient, home-based option, oral testosterone replacement therapy can be an attractive path—particularly when combined with thoughtful monitoring and periodic dose re-assessment.

Who Might Consider Oral TRT—and Who Should Be Cautious

Oral TU may be a good fit for:

• Men with confirmed hypogonadism who prefer to avoid injections
• Those seeking a PK profile designed to avoid supraphysiologic peaks
• Patients comfortable with twice-daily dosing and routine lab/clinic follow-ups

Caution or avoidance is generally prudent in:

• Prostate or male breast cancer
• Severe, symptomatic benign prostatic hyperplasia
• Uncontrolled hypertension or significant, unstable cardiovascular disease
• Men actively trying to conceive (TRT commonly suppresses gonadotropins and reduces fertility potential)
• Individuals with markedly elevated baseline hematocrit

A balanced consultation typically weighs symptoms, lab values, comorbidities, preferences, and logistics—and includes a plan for follow-up BP checks, labs, and dose adjustments.

Limitations and What We Still Don’t Know

• Trial design and duration: Many oral TU trials are single-arm or open-label with modest sample sizes and short follow-up (often up to six months). That limits conclusions on long-term outcomes.
• Population generalizability: Participants were predominantly overweight or obese. How best to titrate in lean, very obese, or older populations remains an active question.
• Comparative data: Head-to-head trials among oral TU options—or direct comparisons versus popular injectable schedules—are limited.
• Long-term outcomes: While TRAVERSE supports cardiovascular safety at the class level for appropriately selected patients, ongoing questions remain around longer-term effects on prostate endpoints, fertility, atrial arrhythmias, and kidney outcomes flagged in some analyses.
• Metabolic therapies: As GLP-1 receptor agonists and other weight-loss drugs become more common, we need more data on how they interact with TRT regarding lean mass, dose needs, and cardiometabolic risk.

How Taurus Meds Approaches Oral TRT Choices

For men considering oral testosterone replacement therapy, Taurus Meds emphasizes:

• Careful confirmation of hypogonadism and shared decision-making about route
• Realistic expectations about benefits and uncertainties
• Structured monitoring that includes BP, hematology, and testosterone targets
• Collaboration with primary care and cardiology when cardiovascular risk is present

That approach helps men choose between Tlando, Jatenzo, Kyzatrex, injectables, or transdermal options based on clinical context and personal priorities—without overpromising outcomes.

Conclusion

Modern oral TU capsules—Tlando, Jatenzo, and Kyzatrex—represent a meaningful expansion in TRT choices. Across Phase 3 programs, they reliably bring average testosterone into the eugonadal range for most hypogonadal men, with no liver toxicity signals and a PK profile designed to avoid large peaks and troughs. The main trade-off to keep in view is small but consistent blood pressure increases detectable on ABPM. For many, that is manageable with baseline assessment and on-therapy monitoring—particularly relative to the practical advantages of an oral regimen.

If you are exploring TRT, an informed conversation with a clinician about diagnosis confirmation, goals, titration options, BP monitoring, and fertility considerations is the best next step. Oral TRT is not magic—but for the right patient, it can be a well-matched and evidence-supported solution.

Disclaimer

This content is for educational purposes only and is not medical advice. Do not start, change, or stop any medication based on this article. Consult a qualified clinician about your specific situation.

Sources

• Marius Pharmaceuticals: Final published Phase 3 data for Kyzatrex (MRS-TU-2019EXT)
• TRAVERSE main results and cardiovascular safety of testosterone therapy
• Ambulatory blood pressure findings with oral testosterone undecanoate
• FDA Summary Review: Tlando (2023)
• FDA Summary Review: Kyzatrex (2022)
• FDA Summary Review: Jatenzo (2019)